Improving operations for the brain's most malignant tumor

August 31, 2018

Important research by Barrow Neurological Institute neurosurgeons and University of Washington (UW) scientists on novel imaging technology for malignant brain tumors was published in the August issue of the Nature journal, Scientific Reports. The research was conducted by Drs. Mark Preul and Evgenii Belykh at the Barrow Neurological Institute Neurosurgery Research Laboratory along with Drs. Leonard Nelson and Eric Seibel from the Department of Mechanical Engineering and the Human Photonics Laboratory at the University of Washington.

The neurosurgeons and scientists evaluated use of state-of-the-art optical technology built into commercial grade operating microscopes used in neurosurgery to detect the glow produced by adding the pro-drug 5-ALA to experimental malignant brain tumors. 5-ALA is approved for administration to patients to increase the detection of the margin of invading brain glioma tumors, and thereby allow for a wider or more extensive brain tumor removal. As the most important visualization tool in daily use for neurosurgery, operating microscopes are gaining advanced functionality with innovative illumination modes.

To ensure surgical success, the neurosurgeon must fully understand the illumination properties and functionality of the microscope, especially within the context of fluorescence-guided tumor resection. The principle of fluorescence-guided tumor resection relies on the use of targeting agents with fluorescent properties that can be administered to patients before or during surgery. These agents are intended to accumulate within and around the tumor tissue or within the cells of the tumor, depending on the selectivity and actions of the fluorophore. The desired diagnostic result is to improve visual differentiation and detection of the tumor tissue margins during surgery based on fluorescence. The most notable recent example of a fluorescent agent developed for tumor detection in neurosurgery is 5-aminolevulinic acid (5-ALA), which is used to indicate the presence of tumors and the border regions of malignant gliomas.

Understanding both the nuances of its fluorescent properties and the effects that occur with changes in excitation intensity and duration of light exposure is critical to optimizing the intraoperative utility of 5-ALA as a guide for the surgeon to discriminate the border region of the tumor. The process of drug signal photobleaching and the reduction of fluorescence that occurs are believed to be directly related to the light intensity of the operating microscope and the duration of exposure.

However, although in wide use, this state-of-the-art imaging has not been thoroughly evaluated for commercial grade operating microscopes used for neurosurgery. The scientific group evaluated for the first time the rate at which the fluorescence signal intensity caused by 5-ALA declines with exposure to light. The scientists found wide variability in the microscopes in neurosurgery for detecting the fluorescence signal and that it bleaches out at variable rate detection. Commercial grade operating microscopes are increasingly outfitted with modules for fluorescence emission detection at various wavelengths. These special illumination modules have become commonplace during neurosurgery for cerebrovascular disorders and are increasingly used for brain tumor resection procedures. Comprehension of the microscope illumination output, fluorescence, and photobleaching can have a profound influence on the suitable protocol a neurosurgeon will follow for tumor resection, especially at the tumor invasive margin. The extent of resection for both low-grade and high-grade gliomas has a weighty impact on patient life expectancy.

Drs. Nelson and Seibel stated: "Our development of standardized methods thus becomes increasingly important for clinical trials and studies that obtain measurements or observations using the surgical microscope in intraoperative fluorescent modalities during the resection of neoplastic brain tissue. Our study advocates for the detailed quantitative analysis of fluorescence for improved accuracy of fluorescence guidance and identification of tumor tissue."

Drs. Preul and Belykh further stated: "However, conventional operating microscopes were not originally designed for quantitative fluorescence measurement, and multiple parameters that can influence fluorescence detection and measurement have not been well described. Our findings about the limitations of quantification of fluorescence with neurosurgical operating microscopes potentially have considerable research and clinical implications. If we're going to use what we believe to be advanced imaging technology, then we need to have confidence that what we're using for fluorescence signal quantitative detection in our clinical systems is proven, reliable, with built-in standards and can be used for patients for their benefit. This is especially true as we develop more sensitive and specific technology to detect and treat such aggressive brain tumors as affected Sen John McCain."
The research was funded by NIH R01 EB016457, PI-Seibel, Advanced biophotonics for image-guided robotic surgery, the Barrow Neurological Foundation, and the Barrow Neurological Institute Newsome Chair in Neurosurgery Research held by Dr. Preul.

St. Joseph's Hospital and Medical Center

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to